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Abstract
Background: In order to attain a better understanding of the interactions between opportunist
fungi and their hosts, we investigated the cytokine profile associated with the inflammatory
response to Candida albicans infection in mice with solid Ehrlich tumors of different degrees.
Methods: Groups of eight animals were inoculated intraperitoneally with 5 × 106 C. albicans 7, 14
or 21 days after tumor implantation. After 24 or 72 hours, the animals were euthanized and
intraperitoneal lavage fluid was collected. Peritoneal macrophages were cultivated and the levels of
IFN-γ, TNF-α, IL-12, IL-10 and IL-4 released into the supernatants were measured by ELISA.
Kidney, liver and spleen samples were evaluated for fungal dissemination. Tumor-free animals and
animals that had only been subjected to C. albicans infection were used as control groups.
Results: Our results demonstrated that the mice produced more IFN-γ and TNF-α and less IL-10,
and also exhibited fungal clearance, at the beginning of tumor evolution. With the tumor
progression, this picture changed: IL-10 production increased and IFN-γ and TNF-α release
decreased; furthermore, there was extensive fungal dissemination.
Conclusion: Our results indicate that solid tumors can affect the production of macrophage
cytokines and, in consequence, affect host resistance to opportunistic infections.
Background
Systemic  Candida albicans infections have a marked
impact on the clinical course and outcome of cancer
patients [1,2]; they are responsible for prolonged hospital
stays, high healthcare costs and significant mortality [3-6].
Although a compromised immune response has been
invoked as a cause of susceptibility to major infections in
tumor-bearing patients, some authors disagree, arguing
that the tumoral condition may, inter alia, result in active
protection against opportunist pathogens [7]. As most
knowledge about Candida  infections in cancer patients
has been obtained from patients with hematological
malignancies [8], and since candidemia is an important
complication in patients with solid tumors, we decided to
study this premise using peritoneal macrophages in mice
bearing solid Ehrlich tumors and infected with C. albicans.
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Previous studies have suggested an important role for
macrophages in the control of candidiasis [9,10]. Those
cells recognizably have a critical role in innate immunity
and in the polarization of the immune adaptive response.
They express complex functions including the production
of cytokines that modulate the responses of other
immune system cells and themselves as well, and bacteri-
cidal/tumoricidal activities [8]. Thus, if macrophage activ-
ities are compromised, the host may become more
susceptible to infections and tumors and this may preju-
dice the results of specific treatments. The peritoneal mac-
rophage population was chosen on the basis of the report
of Bhaumik et al. [11] about macrophage traffic between
the peritoneum and neoplastic tissues. According to those
authors, during the evolution of the neoplasm, macro-
phages originating from the tumor will lodge within the
peritoneal cavity.
Numerous studies have described a significant decrease in
macrophage functions in tumor-bearing hosts [7]. Since
we found no account in the literature about the role of
cytokines in the development of solid tumors, and since
there are divergent views about the evolution and gravity
of C. albicans infection under such circumstances, we pro-
posed to investigate those questions, evaluating the kinet-
ics of cytokine production in mice that bore solid Ehrlich




Male Swiss mice (two months old) from the Animal
House of São Paulo State University, Botucatu, SP, Brazil,
were housed in groups of 3–5 animals and were provided
with food and water ad libitum. All the protocols accorded
with the ethical principles for animal research adopted by
the Brazilian College of Animal Experimentation
(COBEA). This study was approved by Ethical Committee
of School of Sciences, Sao Paulo State University.
Experimental design
The mice were divided into four groups: two BTM groups
inoculated or not inoculated with C. albicans (Ca-BTM
and BTM, respectively); and two control groups, tumor-
free mice that were inoculated or not inoculated with C.
albicans (Ca-CTL and CTL, respectively). The BTM group
animals were killed on days 7, 14 or 21 after tumor
implantation. The Ca-BTM group animals were inocu-
lated intraperitoneally (i.p.) with C. albicans (5 × 106
fungi) on days 7, 14 or 21 after tumor implantation and
were killed 24 or 72 h after C. albicans inoculation. Finally,
the Ca-CTL group animals were sacrificed 24 or 72 h after
C. albicans inoculation.
Ehrlich solid tumor (EST)
This neoplasia, a spontaneous mammary tumor in mice,
does not resolve spontaneously. It may evolve to ascitic
(EAT) or solid forms depending on the route of inocula-
tion (intraperitoneal or subcutaneous respectively). In
this study, the tumor was maintained in the ascitic form
in Swiss mice and the cells were collected according to
Silva et al. [12]. Tumor cells (1 × 107/100 μl) were inocu-
lated subcutaneously into both the BTM and Ca-BTM
groups.
C. albicans inoculum
C. albicans strain FCF 14 was originally obtained from the
fungal collection of the School of Odontology, São Paulo
State University, São Jose dos Campos, SP, Brazil. The
fungi were maintained on Sabouraud medium (Difco
Laboratories, Detroit, Michigan, USA), then cultured in
the same medium for 24 h at 37°C. The colonies were
resuspended and washed twice. Fungal viability was deter-
mined by cotton blue staining and the concentration was
adjusted to 5 × 107 viable C. albicans/ml [13].
Collection of the biological material and macrophage 
culture
Mice were sacrificed using CO2 euthanasia, and peritoneal
cells were collected by washing the peritoneal cavity with
10 ml ice-cold sterile phosphate buffered saline (PBS), pH
7.4. The suspension was centrifuged and the cells were
resuspended in 1 ml RPMI-1640 (Nutricell, Campinas,
SP, Brazil) containing 10% heat-inactivated fetal calf
serum (Gibco BRL, Grand Island, NY, USA). The cell con-
centration was adjusted to 2 × 106 macrophages/ml, as
judged by the uptake of 0.02% neutral red. The peritoneal
cells were placed in 96-well flat-bottom microtiter plates
(Costar, Cambridge, MA, USA) and incubated for 2 h at
37°C and 5% CO2 in a humidified chamber to allow mac-
rophages to adhere and spread. Non-adherent cells were
removed by washing the wells three times with RPMI, and
the remaining adherent cells (>97% macrophages as
assessed by morphological examination) were used for
experiments. The macrophages were cultured at 37°C, 5%
CO2, in RPMI-1640 with or without 10 μg/ml LPS
(Sigma) as an internal control for macrophage activity
(data not shown). After 24 h, the cell-free supernatants
were harvested and stored at -70°C pending cytokine
analysis. Finally, the peritoneal fluid and liver, spleen and
kidney fragments were subjected to microbiological eval-
uation.
Direct organ culture
Ten fragments (2 × 2 mm) of liver, spleen and kidney were
placed on 15 × 90 mm Sabouraud agar plates at 37°C for
5 days according to a previously-described method [14].
The yeast colonies on the fragments were counted and theBMC Infectious Diseases 2009, 9:98 http://www.biomedcentral.com/1471-2334/9/98
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results were expressed as the frequency of Candida-posi-
tive organ fragments.
Fungal loads in PF
PF (30 μl) was placed on 15 × 90 mm Sabouraud agar
plates at 37°C. The yeast colonies were counted on the 5th
day and the fungal loads were determined by counting the
colony-forming units (CFU).
Cytokine analysis
TNF-α, IL-12, IFN-γ, IL-10 and IL-4 levels were measured
in the cell-free supernatants of the peritoneal cell cultures
using a Cytokine Duo-Set Kit (R&D Systems, Minneapolis,
USA). Each sample was analyzed in duplicate.
Statistical analysis
Linear regression analysis was used to determine the cor-
relation between tumor evolution and fungal installation
and dissemination. Cytokine production data were ana-
lyzed using one-way ANOVA with the Tukey-Kramer post-
test [15]. All statistical tests were conducted using Graph-
Pad InStat version 3.0 for Windows (GraphPad Software,
San Diego, California, USA) and p < 0.05 was taken as the
criterion for statistical significance.
Results
Tumor implant
After the EAT cells were introduced in the subcutaneous
tissue (EST), the mice developed at the inoculation site a
firm, tangible, whitish coloring and relatively movable
mass. This tumor showed continuous and progressive
growth, leading to the death of the animals at about the
25th day after implantation.
Fungi installation and dissemination
CTL and BTM animals showed no fungi in any of the sam-
ples analyzed or at any time during the experiment.
The frequencies of C. albicans-positive animals in the Ca-
CTL and Ca-BTM groups are summarized in Table 1. In
the Ca-CTL group, intraperitoneal introduction of the fun-
gus resulted in acute systemic candidiasis, with dissemina-
tion to the spleen, liver and kidneys. At 72 h, the
frequency of C. albicans-positive samples decreased, both
internally and at the inoculation site, suggesting a ten-
dency towards resolution. In the Ca-BTM group, only one
animal after seven days of tumor evolution was Candida-
positive 24 h pi. At 14 days of tumor evolution, the ani-
mals presented a similar picture to the control group. At
21 days, we observed that all the mice showed fungi, but
there was exacerbation; the cultivation of tissue samples
revealed more viable fungi than in the control group ani-
mals [data not shown]. We observed a positive correlation
between tumor evolution and the frequency of PF and/or
organ colonization after 72 h (r = 0.99; p = 0.04).
Cytokine determination
In the present study, IL-12 production was only observed
in Ca-CTL at 24 h (5.44 ± 1.95 pg/ml).
The level of TNF-α in Ca-CTL increased at 24 h and
decreased at 72 h pi (Fig. 1). In BTM, levels of this
cytokine increased initially, but decreased with the tumor
progression (Fig. 2). A challenge with C. albicans (Ca-BTM
group) did not change this picture: TNF-α increased dur-
ing the first period of tumor progression, but there was a
decrease at 72 h pi after the 14th day (Fig. 3).
Table 1: Frequency of Candida albicans-positive animals from the Ca-CTL and TBM-Ca groupsa.
Experimental Group Candida infection hours Organsb
Peritoneum Spleen Kidney Liver
Ca-CTL 24 91.7 ± 14.4 80.3 ± 14.4 48.3 ± 44.8 8.3 ± 14.8
72 50.0 ± 0 66.7 ± 28.9 8.3 ± 14.8 8.3 ± 14.8
Ca-TBM
7th day
24 25.0 ± 0 25.0 ± 0 8.3 ± 14.8 8.3 ± 14.8
72 0 0 8.3 ± 14.8 8.3 ± 14.8
Ca-TBM
14th day
24 100.0 ± 0 91.7 ± 14.4 33.3 ± 14.4 8.3 ± 14.8
72 50.0 ± 25.0 58.3 ± 28.9 25.0 ± 25.0 25.0 ± 0
Ca-TBM
21th day
24 100.0 ± 0 66.7 ± 14.4 41.7 ± 52.0 25.0 ± 25.0
72 75.0 ± 0 75.0 ± 25.0 50.0 ± 25.0 58.3 ± 28.9
a The results shown are the average of triplicate experiment. For each experiment, four animals per group were used.
b Data expressed as mean frequency of Candida-positive animals (%) ± SD.BMC Infectious Diseases 2009, 9:98 http://www.biomedcentral.com/1471-2334/9/98
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To evaluate the immune protective response, we investi-
gated INF-γ production. In our study, macrophages from
Ca-CTL group mice showed an increase in IFN-γ produc-
tion 24 h pi as at 72 h pi (Fig. 1). Although the IFN-γ levels
at 72 h remained higher than in the controls, they were
significantly lower than those obtained at 24 h (Fig. 1).
This datum correlates positively with the fungal concen-
tration in the peritoneal environment, i.e. higher at 24 h
than at 72 h. BTM macrophages showed increased IFN-γ
production only at the 7th day of tumor progression (Fig.
2). In Ca-BTM, the quantity of IFN-γ measured was higher
at the 7th and 14th days of tumor progression (Fig. 3).
To evaluate the anti-inflammatory immune response, we
investigated IL-4 and IL-10 production. With rare excep-
tions, we found no IL-4 in our animals. We verified that
the peritoneal macrophages of CTL mice (stimulus-free)
could produce IL-10. After inoculation with the fungus,
the production of this cytokine decreased at 24 h and
returned to base level at 72 h pi (Fig 3A). BTM mice
showed a significant increase in IL-10 production
Release of TNF-α, IFN-γ and IL-10 spontaneously produced by peritoneal macrophages in the Ca-CTL group Figure 1
Release of TNF-α, IFN-γ and IL-10 spontaneously produced by peritoneal macrophages in the Ca-CTL group. 
Data are expressed as mean ± SEM. * significantly different from CTL, # vs. Ca-CTL 24 h. P < 0.05; n = 4/group. ANOVA; 
Tukey's post-test.
Release of TNF-α, IFN-γ and IL-10 spontaneously produced by peritoneal macrophages in the TBM group Figure 2
Release of TNF-α, IFN-γ and IL-10 spontaneously produced by peritoneal macrophages in the TBM group. Data 
are expressed as mean ± SEM. * significantly different from CTL, # vs. BTM 7th day; § vs. TBM 14th day. P < 0.05; n = 4/group. 
ANOVA; Tukey's post-test.BMC Infectious Diseases 2009, 9:98 http://www.biomedcentral.com/1471-2334/9/98
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throughout tumor progression. In the Ca-BTM group, this
cytokine decreased after 7 and 14 days of tumor progres-
sion (Fig. 3); at 21 days it increased 24 and 72 h after Can-
dida infection.
Taken together, our results show that at the outset of
tumor progression, BTM group animals produced large
quantities of TNF-α and IFN-γ and little IL-10, and they
showed fungal clearance. With the tumor progressed, this
picture changed: IL-10 production increased and TNF-α
and IFN-γ production decreased, and the animals showed
extensive fungal dissemination. Our results also indicate
that the tumoral condition suppressed the production of
macrophage cytokine IL-12.
Discussion
Deterioration of immune function and an increased inci-
dence and lethality of infectious diseases caused by Cand-
ida albicans have been observed in tumor patients [16,17].
Although the mechanisms involved in this association are
not totally clear, macrophages are known to play a signif-
icant part.
Release of TNF-α, IFN-γ and IL-10 spontaneously produced by peritoneal macrophages in the Ca-TBM group Figure 3
Release of TNF-α, IFN-γ and IL-10 spontaneously produced by peritoneal macrophages in the Ca-TBM group. 
Data are expressed as mean ± SEM. * significantly different from TBM, # vs. Ca-CTL. P < 0.05; n = 4/group. ANOVA; Tukey's 
post-test.BMC Infectious Diseases 2009, 9:98 http://www.biomedcentral.com/1471-2334/9/98
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We studied this association in mice with EST, a spontane-
ous mammary mice tumor of which the development has
been related to the activity of the immune system. In a
previous study we verified that this tumor significantly
decreased the overall resistance of mice to systemic C. albi-
cans  infection and that this effect was associated with
alterations in the oxidative metabolic activity of perito-
neal macrophages [18]. As cytokines are deeply involved
in both processes (host immunosurveillance against
invading pathogens and malignancies), we investigated
the possibility that the tumoral condition affects the pro-
file of cytokines released by peritoneal macrophages from
tumor-bearing and/or C. albicans-infected mice. We stud-
ied the expression of IFN-γ and IL-12, the major cytokines
produced by macrophages and crucial for a vigorous
immune response [19]. We also evaluated the production
of IL-10 and IL-4, strong inhibitors of macrophage activa-
tion and the inflammatory response [20-23].
We began the study by identifying the cytokines produced
by peritoneal macrophages from normal mice (CTL
group). We verified that, although incapable of producing
IL-12 or IL-4, those cells produced negligible quantities of
IFN-γ and significantly more IL-10 than other cytokines.
Thus, as observed in rodent strains and also in humans,
resident peritoneal macrophage from Swiss mice bear
some similarities to the M2 subtype, which typically pro-
duce IL-10 [24-26].
Compared with resident peritoneal cells from animals of
CTL group, the macrophages from Candida-infected mice
(Ca-CTL group) produced less IL-10 but copious amounts
of IFN-γ and IL-12. The capacity to elaborate high levels of
IL-12 and low levels of IL-10 is characteristic of M1 mac-
rophages [27]. M1 macrophages are strong promoters of
Th1 immune responses and exert antimicrobial activities,
resulting from their ability to secrete reactive nitrogen and
oxygen species (NO, peroxynitrite, hydrogen peroxide,
superoxide) [19]. In fact, in this microenvironment, the
fungal load is obliterated or is markedly reduced. In the
absence of fungi, the peritoneal macrophages exhibited
the M2 profile again.
Thus, the introduction of C. albicans into the peritoneal
environment leads to changes of the macrophage pheno-
type. In agreement with other studies, this reinforces the
idea that, even when polarized, Swiss peritoneal macro-
phages can integrate different signals adequately and can
convert their phenotype from M2 to M1 and vice versa.
Tumor progression also provoked alterations that
changed the peritoneal macrophage profile: at the outset
of the neoplastic process, BTM peritoneal macrophages
demonstrated consistent TNF-α production and moderate
IFN-γ and IL-10 production. Thus, either they exhibited a
functionally mixed population or adopted a rather pro-
miscuous activation state, which could however be ideally
suited for diminishing tumor immunosurveillance [28].
With the tumor progressed, the macrophages showed a
profile similar to the M2 population. At this time, they
became refractory to further stimulation; even when pro-
voked with C. albicans, they persisted in exhibiting an
immunosuppressive phenotype and could not mount an
effective anti-fungal response. These results support the
findings of Kuang et al. [29], who suggest that new stimuli
can fail to stimulate pre-activated cells and subsequently
exhausted monocytes/macrophages.
The fact that those phenomena occurred at a site distant
from the neoplastic mass indicates that the solid Ehrlich
tumor provokes alterations in systemic levels. This may
have occurred because of mediators derived from tumor
cells and/or of derivative elements in the tumor stroma
[29-34]. It is still possible that, along of the progression of
the neoplasm, we have collected macrophages originating
from a tumor itself. Working with the subcutaneous vari-
ety of AK-5, a histiocytic rat tumor, Bhaumik et al. [11]
demonstrated hyperactive macrophages accumulated in
the peritoneum during tumor progression, and the
number of those macrophages decreased drastically when
the tumor regressed. Direct labeling of these cells with
vital dyes showed that they migrated to and from the
tumor site.
From Kuang et al. [29], macrophages recruited into the
cancer from the circulation may be transiently activated
while approaching the stroma surrounding the tumor.
When they are in close proximity to the tumor cells,
tumor-derived factors would act on them, inducing the
M2 phenotype [35]. Our results showed similarities with
this assertion, since after seven days of tumor evolution
we detected a mixed population of peritoneal macro-
phages, including pro-inflammatory ones, and with the
tumor progression, this population re-acquired a predom-
inantly pro-tumoral M2 subset. As those macrophages
have no microbicid profile, they turn the peritoneal cavity
into a microenvironment favorable for persistent infec-
tion. In fact, with the tumor progression, the animals
become more susceptible to Candida, as shown by its per-
manence at the inocolum site, and its dissemination is
facilitated.
Conclusion
Our results showed that at the outset of tumor progres-
sion, the mice produced more IFN-γ and TNF-α and less
IL-10; they also exhibited fungal clearance. With the
tumor progression, this picture changed: IL-10 produc-
tion increased and IFN-γ and TNF-α release decreased; fur-
thermore, there was extensive fungal dissemination. ThisBMC Infectious Diseases 2009, 9:98 http://www.biomedcentral.com/1471-2334/9/98
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picture indicates that solid tumor progression modulates
the cytokine profile of peritoneal macrophages, possibly
because tumor macrophages continually enter the circula-
tion; a development that may compromise the systemic
immune response.
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